Revumenib, an investigational drug that inhibits a protein called menin, had minimal severe adverse effects when administered orally twice a day, according to results from a phase 1 clinical trial involving 68 participants with relapsed or refractory acute leukemia. The trial specifically tested the agent among patients whose leukemias were characterized by rearrangement of the KMT2A gene or variation of the NPM1 gene; these types of leukemias depend on menin.
Source: JAMA Online First